KRSA · XBRL financial data

Korsana Biosciences financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (KRSA's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26†Sep 30, 2026
Revenue	0*	0	0	194	year only	81	93	875	1,025*	0	0*	—
Research and development	24*	44	105	81	56*	36	56	348	519*	730	0*	42
General and administrative	1,771*	1,574	1,279	1,241	1,248*	1,502	1,709	1,533	1,344*	2,479	1,771	6
Total operating expenses	1,795*	1,618	1,384	1,322	1,304*	1,538	1,765	1,881	1,863*	3,209	1,771	48
Operating income (loss)	(1,795)*	(1,618)	(1,384)	(1,128)	502*	(1,457)	(1,672)	(1,006)	(838)*	(3,209)	(1,771)	(48)
Income tax expense (benefit)	year only	—	—	—	year only	—	—	0	0*	—	—	0
Net income (loss)	(1,694)*	(1,542)	(1,322)	(723)	530*	(1,429)	(324)	(976)	(799)*	(3,177)	(1,755)	(46,425)
Earnings per share, basic USD per share	—	(0.62)	(0.53)	(0.29)	0.21*	(0.56)	(0.11)	(0.30)	—	(0.76)	(0.41)	(3.19)
Earnings per share, diluted USD per share	—	(0.62)	(0.53)	(0.29)	0.21*	(0.56)	(0.11)	(0.30)	—	(0.76)	(0.41)	(3.19)
Weighted average shares, basic thousands of shares	—	2,494	2,510	2,526	2,542*	2,556	3,071	3,225	3,857*	4,205	4,251	13,526
Weighted average shares, diluted thousands of shares	—	2,494	2,510	2,526	2,542*	2,556	3,071	3,225	3,857*	4,205	4,251	13,526

† Share count changed about 10x in the period ending 2026-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (KRSA's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26†Sep 30, 2026
Cash and cash equivalents	7,571	5,696	4,588	2,872	3,232	3,639	3,006	4,568	3,240	2,823	1,391	456,221
Accounts receivable	0	—	—	44	556	581	525	100	1,000	0	0	—
Prepaid and other current assets	—	—	—	—	—	—	—	—	461	—	—	4,428
Total current assets	8,024	6,014	4,715	3,548	4,225	4,497	4,020	5,065	4,635	3,089	1,514	460,649
Property and equipment, net	0	0	0	0	0	0	0	0	0	66	66	367
Right-of-use asset	0	—	—	—	—	—	—	—	0	—	—	967
Total assets	13,374	11,364	10,065	8,898	9,575	9,847	9,370	10,415	9,985	8,505	6,930	462,084
Accounts payable	1,198	741	651	304	390	483	462	480	508	457	1,597	1,611
Total current liabilities	2,086	1,441	1,282	700	725	1,067	800	877	900	1,714	1,843	44,197
Lease liability, non-current	—	—	—	—	—	—	—	—	0	—	—	984
Total liabilities	—	—	—	—	—	—	—	—	13,027	—	—	45,557
Accumulated deficit	(264,417)	(265,959)	(267,299)	(268,022)	(267,492)	(268,921)	(269,245)	(270,221)	(271,020)	(274,197)	(275,952)	(113,025)
Total stockholders' equity	11,288	9,923	8,783	8,198	8,850	8,780	8,570	9,538	9,085	6,791	5,087	391,563
Total liabilities and equity	13,374	11,364	10,065	8,898	9,575	9,847	9,370	10,415	9,985	8,505	6,930	462,084
Common shares outstanding (cover page) thousands of shares	2,710	2,710	2,710	2,710	2,710	3,210	3,337	3,925	4,330	4,330	4,681	45,541

† Share count changed about 10x in the period ending 2026-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (KRSA's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26†Sep 30, 2026
Net income (loss)	(1,694)*	(1,542)	(1,322)	(723)	530*	(1,429)	(324)	(976)	(799)*	(3,177)	(1,755)	(46,425)
Stock-based compensation	103*	181	184*	138*	122*	114	114*	118*	95*	58	51*	17,311*
Net cash from operating activities	(1,541)*	(1,871)	(1,106)*	(1,716)*	360*	(968)	(503)*	(264)*	(1,579)*	(1,176)	(1,432)*	(46,829)*
Purchases of property and equipment	—	—	—	—	—	0	0*	0*	—	66	0*	231*
Net cash from investing activities	0*	—	—	0*	0*	0	0*	0*	—	(66)	0*	(231)*
Proceeds from issuing common stock	0*	0	0*	0*	0*	1,375	0*	0*	0*	—	—	—
Net cash from financing activities	0*	0	0*	0*	0*	1,375	(130)*	1,826*	251*	825	0*	351,096*
Net change in cash	(1,537)*	(1,875)	(1,108)*	(1,716)*	360*	407	(633)*	1,562*	(1,328)*	(417)	(1,432)*	304,036*

† Share count changed about 10x in the period ending 2026-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Korsana Biosciences	456,221	not reported	(46,829)*	45.5M	27.5 quarters	Q3 FY26 10-QSep 30, 2026
America Great Health	29	26	1.7*	21.2B	—	Q3 FY26 10-QMar 31, 2026
AbbVie	10,774,000	17,404,000	7,606,000*	1.8B	—	Q3 FY26 10-QSep 30, 2026
Abeona Therapeutics	56,229	11,380	(17,496)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Abbott Laboratories	4,052,000	13,013,000	1,737,000*	1.7B	—	Q3 FY26 10-QSep 30, 2026
Arbutus Biopharma	19,171	1,014	(6,018)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
Abvc Biopharma	32	not reported	(244)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Acadia Pharmaceuticals	322,365	342,291	11,503*	172.8M	—	Q3 FY26 10-QSep 30, 2026
AC Immune	26,795	year only	year only	101.7M	—	Q4 FY25 20-FDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 3:10 AM ET. The filing on SEC.gov is the record.